Archives
-
Verapamil HCl Workflows for Calcium Signaling
2026-09-13
Verapamil HCl provides a practical perturbation tool for L-type calcium channel studies, with applications spanning calcium channel inhibition in myeloma cells, transporter biology, and inflammatory disease models. This guide translates the evidence into staged assay workflows, controls, and troubleshooting decisions for more reproducible results.
-
Carfilzomib (PR-171): A Proteostasis Assay Guide
2026-09-12
Carfilzomib (PR-171) is an irreversible proteasome inhibitor whose value extends beyond simple viability testing. This guide develops a mechanism-to-readout framework linking proteasome-mediated proteolysis inhibition with ER-stress biomarkers, apoptosis interpretation, and combination-assay design.
-
METTL16–SENP3–LTF Drives HCC Ferroptosis Resistance
2026-09-11
Wang et al. identify a METTL16–SENP3–LTF axis that lowers the labile iron pool and protects hepatocellular carcinoma cells from ferroptosis. By integrating m6A-focused molecular assays with organoids, xenografts, genetically modified mice, and human samples, the study connects RNA regulation, protein stability, iron handling, and tumor progression.
-
LL-37, KE-18, and KR-12 in Biofilm Control
2026-09-11
The reference study showed that the human host defense peptide LL-37 and its truncated mimetics KE-18 and KR-12 can separate antimicrobial killing from antibiofilm activity across Candida albicans, Staphylococcus aureus, and Escherichia coli. Its key practical contribution is methodological: MIC measurements and crystal violet biofilm assays should be interpreted as complementary rather than interchangeable readouts.
-
Prestained Protein Marker: Triple Color 10–250 kDa
2026-09-10
F4005 is a ready-to-use Triple color protein ladder for tracking SDS-PAGE separation, checking transfer, and estimating apparent protein size across 10–250 kDa. It is appropriate for denaturing gel and Western blot workflows, including EDTA-sensitive Phosbind systems, but it should not be treated as an exact protein-identification standard or as quantitative evidence of transfer efficiency.
-
Ionomycin Free Acid: Calcium Ionophore Guide
2026-09-10
Ionomycin free acid is a calcium ionophore research reagent that increases membrane-mediated calcium ion transport and intracellular calcium. The product is supplied in ethanol, has a reported purity of at least 95%, and supports controlled studies of calcium signaling, oocyte activation, and hypothesis-driven cancer biology.
-
S63845 MCL1 Inhibitor Workflow Guide
2026-09-09
Build a cleaner apoptosis workflow with S63845 by linking MCL1 inhibition to BAX/BAK activation, mitochondrial permeabilization, and orthogonal cell-death readouts. The guide also shows how to distinguish genuine apoptotic enhancement from ferroptosis-related assay confounding in hematological cancer research.
-
L1023 Anti-Cancer Compound Library Workflow
2026-09-09
Build pathway-aware cancer screens with a pre-dissolved compound collection spanning kinase, proteostasis, epigenetic, and apoptosis targets. Pair L1023 phenotypic screening with STING mechanism-informed follow-up to distinguish pathway modulation from nonspecific cytotoxicity.
-
MCL-1 Dependence in Breast Cancer and Apoptosis
2026-09-08
The reference study shows that MCL-1 supports established breast tumors primarily through its canonical anti-apoptotic function, rather than through an independent non-apoptotic activity. By combining genetic deletion, pharmacological inhibition, tumor models, and BAX/BAK dependency analysis, the authors connect MCL-1 targeting to mitochondrial apoptosis and identify implications for breast cancer and stem-cell research.
-
Gastrodin, AT1 Signaling, and Astrocyte Reactivity
2026-09-08
The reference study shows that activated microglia can reshape astrocyte renin–angiotensin system and inflammatory responses through an AT1-linked RAS–SIRT3 pathway. Its conditioned-medium model and azilsartan perturbation experiments provide a useful framework for separating microglia-to-astrocyte signaling from direct drug effects.
-
Cytochalasin B Workflows for Actin Assays
2026-09-07
Build more interpretable actin assays with Cytochalasin B, a reversible perturbation tool for migration, uptake, cytokinesis, and cytoskeletal drug discovery. This guide combines dose-finding, orthogonal toxicity checks, and troubleshooting with lessons from a modern genotoxicity testing workflow.
-
Norovirus Co-opts NINJ1 for Selective Secretion
2026-09-07
Song et al. show that murine norovirus exploits NINJ1-mediated plasma membrane rupture to release the viral protein NS1 while simultaneously promoting broad cellular DAMP release. Combining CRISPR screening, cell biology, mutagenesis, and mouse infection models, the study identifies a caspase-3– and NINJ1-dependent unconventional secretion pathway with implications for host–virus interaction research.
-
DiscoveryProbe FDA-approved Drug Library in Context
2026-09-05
A state-aware screening workflow turns a clinically annotated compound collection into a sharper tool for drug repositioning and cancer research drug screening. The approach pairs broad phenotypic coverage with time-resolved controls that help distinguish genuine resistance biology from culture-induced assay variation.
-
Bestatin-Derived Inhibitors of IRAP and ERAP1
2026-09-04
The reference study develops a stereoselective route for functionalizing Bestatin’s α-hydroxy-β-amino acid scaffold and applies structural biology to improve inhibitor potency and selectivity. Its most important result is a cell-active, low-nanomolar IRAP inhibitor with more than 120-fold selectivity over homologous aminopeptidases, while X-ray structures identify GAMEN-loop interactions as an underappreciated determinant of recognition.
-
15-PGDH Inhibition Supports Muscle Recovery
2026-09-04
A 2026 PNAS study shows that inhibiting 15-PGDH can improve muscle stem cell activity, regenerated myofiber growth, and force recovery during semaglutide-associated weight loss in obese mice. The work suggests that combining a 15-PGDH inhibitor with a GLP-1 receptor agonist may preserve regenerative muscle quality without weakening weight-loss efficacy.